Third Wave Technologies Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Third Wave Technologies Inc.
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.